Deferred Tax Assets, Valuation Allowance of Mersana Therapeutics, Inc. from 31 Dec 2016 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Mersana Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2016 to 31 Dec 2024.
  • Mersana Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $262,845,000, a 9.8% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Mersana Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $262,845,000 +$23,377,000 +9.8% 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q4 2023 $239,468,000 +$48,880,000 +26% 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q4 2022 $190,588,000 +$60,537,000 +47% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q4 2021 $130,051,000 +$52,676,000 +68% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q4 2020 $77,375,000 +$28,486,000 +58% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q4 2019 $48,889,000 -$5,051,000 -9.4% 31 Dec 2019 10-K 26 Feb 2021 2020 FY
Q4 2018 $53,940,000 +$21,338,000 +65% 31 Dec 2018 10-K 28 Feb 2020 2019 FY
Q4 2017 $32,602,000 +$6,611,000 +25% 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q4 2016 $25,991,000 31 Dec 2016 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.